The Global PD-1/PD-L1 Inhibitors Industry stands at the threshold of an unprecedented surge, poised to achieve a remarkable valuation of US$123.3 billion by 2033. This forecasted trajectory, underpinned by an impressive Compound Annual Growth Rate (CAGR) of 9.6%, foresees a valuation of US$49.5 billion as early as 2023. The driving force behind this monumental growth …